Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

On July 9, 2025, Sironax announced granting Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, which is designed to enhance the delivery of therapeutics across the blood-brain barrier (BBB)1 3 4.

The BDM platform is described as a differentiated BBB-crossing technology suitable for various therapeutic modalities, enabling improved brain penetration for potential neurological drugs1 3.

Sironax will retain rights to develop selected therapeutic assets using the BDM platform, allowing for further internal R&D alongside the Novartis partnership1 3 4.

The partnership aims to combine Novartis's global neuroscience expertise with Sironax’s innovation in drug delivery for neurological conditions3 4.

This deal is reportedly valued up to $175 million, reflecting the strategic importance of BBB technology in neuroscience drug development2.

Recent biopharma M&A activity in 2025 has seen a focus on CNS (central nervous system) and neurological assets, with Novartis and others making significant moves in the space, complementing this Sironax agreement5.

While additional details or updates on Revolution, Iambic, Sernova, and Eledon were requested, the provided search results do not include their recent deal activity; only the Novartis-Sironax agreement is detailed in current news.